Takeda and Japanese venture end oncology research alliance
This article was originally published in Scrip
Executive Summary
Takeda and the Japanese bioventure CanBas have terminated a global oncology R&D collaboration which was focusing on a novel therapy for lung cancer and mesothelioma.